Search Within

Andrew D Zelenetz

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (57)
  2. Journal Article (30)
  3. Research Letter (3)
  4. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (91)
  2. Department of Medicine (91)
  3. Hematologic Malignancies, Division of (91)
  4. Lymphoma (91)
  5. Sloan Kettering Institute Postdocs (91)
  6. Survivorship Research (60)

More Groups

People
  1. Maria Palomba (65)
  2. Anita Kumar (63)
  3. Paul Hamlin (63)
  4. Ariela Noy (62)
  5. Alison Moskowitz (58)
  6. Steven Horwitz (57)

More People

Years
  1. 2025 (2)
  2. 2024 (5)
  3. 2023 (17)
  4. 2022 (10)
  5. 2021 (13)
  6. 2020 (16)

More Years

Publications
  1. Blood (46)
  2. Hematological Oncology (9)
  3. Journal of Clinical Oncology (6)
  4. Blood Cancer Journal (5)
  5. Blood Advances (4)
  6. Haematologica (4)

More Publications

Publishers
  1. American Society of Hematology (50)
  2. Wiley Blackwell (9)
  3. American Society of Clinical Oncology (6)
  4. Nature Publishing Group (5)
  5. Ferrata Storti Foundation (4)
  6. Taylor & Francis Group (3)

More Publishers

Results (91)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Infectious complications in patients with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) treated with the anti-CD20xCD3 bispecific antibody (BsAb) mosunetuzumab
    Meeting Abstract

    Shahid, Z.; Okwali, M.; Joseph, A.; Seo, S. K.; Lue, J. K.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of limited stage high grade B-cell lymphoma with MYC/BCL2 and/or BCL6 rearrangements: A single center experience
    Meeting Abstract

    Lue, J. K.; Luttwak, E.; Caron, P.; Boardman, A. P.; David, K. A.; Rivas-Delgado, A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma -Real world experience
    Meeting Abstract

    Luttwak, E.; Ganesan, N.; Boardman, A. P.; Caron, P.; David, K. A.; Rivas-Delgado, A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Potent CD8+T-cell proliferation and effector differentiation following subcutaneous (SC) mosunetuzumab administration in patients with untreated, high tumor-burden follicular lymphoma (FL)
    Meeting Abstract

    Falchi, L.; Lin, Y. H.; Melendez, L.; Ghione, P.; Owens, C.; Hamlin, P. A.; Lue, J. K.; Epstein-Peterson, Z. D.; Kumar, A.; Palomba, M. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Subcutaneous (SC) mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): First results of a multicenter phase 2 study
    Meeting Abstract

    Falchi, L.; Okwali, M.; Ghione, P.; Owens, C.; Hamlin, P. A.; Lue, J. K.; Epstein-Peterson, Z. D.; Palomba, M. L.; Kumar, A.; Torka, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Predicting toxicities in older adults with non-Hodgkin lymphoma (NHL) receiving systemic chemotherapy: A prospective geriatric assessment (GA) study
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-life experience with lenalidomide plus anti-CD20 antibodies for the treatment of patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Cassanello, G.; Rivas-Delgado, A.; Luna De Abia, A.; Corona, M.; Luttwak, E.; Okwali, M.; Isgor, I.; Galera, P.; Boardman, A. P.; Caron, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Genetic alterations in follicular lymphoma predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Lee, J.; Fregonese, B.; Hajj, C.; Cedarquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save